First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors
口服生物可利用血管破坏剂 DX1002 对晚期实体肿瘤患者进行的首次人体 1 期研究
期刊:Cell Reports Medicine
影响因子:11.7
doi:10.1016/j.xcrm.2025.101969
Xiao-Li Wei, Hao-Xiang Wu, Dan-Yun Ruan, Feng Wang, Li Xu, Yu-Hong Li, Yu-Xiang Ma, Zhi-Qiang Wang, Yun-Peng Yang, Liang-Wei Tang, Bao-Lin Chen, Zhi-Quan Yong, Rui-Hua Xu, Hong-Yun Zhao